Diphenylhydantoin (DPH) therapy, often used in treating epileptic seizures, can cause anemia in some patients. A 26-year-old female suffered from convulsions due to encephalitis and was placed on DPH therapy. About two months after the initiation of DPH therapy, her hemoglobin level was 3.8 g/dL. Her anemia improved after the discontinuation of DPH, confirming that the anemia was caused by DPH. Pure red-cell aplasia (PRCA) combined with hemolytic anemia was indicated by results such as erythroid aplasia, an increased LDH level, and a decreased haptoglobin level. PRCA complicated by hemolytic anemia could be responsible for anemia associated with DPH.
Introduction
Pure red-cell aplasia (PRCA) is a rare disease characterized by the selective reduction or absence of erythroid precursors in the bone marrow and peripheral blood despite normal platelet and white blood cell counts. Drug-induced PRCA is reported to account for less than 5% of PRCA cases (1) . While drugs such as isoniazid and azathioprine have been established as inducers of PRCA (1, 2) , little is known about the mechanisms of diphenylhydantoin (DPH)-induced severe anemia.
In this paper, we report a pregnant woman with severe anemia due to the periodic use of DPH, and we review previous reports addressing PRCA's association with DPH therapy.
Case Report
This is a case report of a 26-year-old female patient who presented with convulsions and disturbed consciousness due to brainstem encephalitis in mid-July 2009, at 19 weeks of gestation. She was treated with acyclovir, meropenem, and steroids. A week later, while she was mechanically ventilated, we initiated intravenous administration of DPH (250 mg/day), which resulted in the improvement of her symptoms and her eventual removal from the ventilator. From mid-August, she was prescribed oral DPH at 300 mg/day. A blood test performed in late August showed a hemoglobin (Hb) level of 10.4 g/dL. Around the end of August, the patient started experiencing nausea, loss of appetite, and general fatigue. In early October (at 29 weeks and 5 days of gestation), she also experienced palpitations and shortness of breath, which prompted her to visit our hospital. Blood test results indicated a Hb level of around 3 g/dL, indicating severe anemia, and the patient was subsequently hospitalized. The patient lacked any noteworthy family history or preexisting conditions. The patient had persistent nausea, and an examination of her general condition revealed pale bulbar conjunctiva and mild tachycardia with a pulse rate of 92 beats per minute.
The patient's laboratory data are summarized in Table 1 . These results indicated a marked reduction in the RBC count and a low reticulocyte count despite normal WBC and Table 1 ). The serum DPH concentration was as low as 2.4-4.8 μg/mL (mean value, 3.6; reference value, 10-20 μg/mL) throughout the course of treatment.
The patient's clinical course is shown in Fig. 1 . For the Table 2 . Characteristics of Cases with Diphenylhydantoin-induced Pure Red-cell Aplasia safety of the fetus, the patient received two units of packed RBC transfusions per day for three consecutive days (a total of six units of packed RBCs). Because the patient's symptoms had been attributed to her drug regimen, DPH was discontinued and replaced with sodium valproate at a dosage of 600 mg/day. Subsequently, the patient's nausea disappeared, and she regained her appetite. Bone marrow aspiration three days after the discontinuation of DPH showed normal cellularity with decreased erythroblasts. Although the myeloid-toerythroid ratio was elevated to 5.3 (normal range, 2-4), the erythroid precursors showed normal maturation without morphological abnormality, indicating rapid resolution of erythropoiesis. The proportion of erythroblasts was normal, with polychromatic erythroblasts predominant. There were no dysplastic findings in granulocytes and magakaryocytes, so ineffective hematopoiesis was not suspected. Chromosomal analysis of the bone marrow showed normal karyotypes except for a "46, XX, t(1;5) (p36.1;q13)" out of 30 cells. Based on the International System for Human Cytogenetic Nomenclature (2009), this abnormality was not identified as clonal. The patient's reticulocyte count rose steadily as her anemia improved (Fig. 1) . The drug-induced lymphocyte stimulation test with DPH was positive. A blood test performed one month after hospital admission showed an RBC count of 3.20×10 6 /μL, an Hb level of 11.4 g/dL, and a reticulocyte count of 70,400/μL, which indicated the sustained improvement of anemia. The patient had a normal delivery in early December 2009, at 38 weeks and 4 days of gestation. Both the mother and the child were well, with no deformities noted in the child.
Discussion
The patient in the present study had normal WBC and Plt counts while showing a reduced RBC count. Discontinuation of the DPH, suspected of inducing the disorder, resulted in an immediate increase in the reticulocyte ratio and reticulocyte count, which led to sustained improvement of anemia. These findings led to the clinical diagnosis of DPH-induced PRCA. Anemia during pregnancy is caused by an increase in total blood volume, which is sometimes observed in otherwise healthy pregnant women (3). However, the anemia suffered by the patient in the present study was far more severe. The treatment involved nothing more than the discontinuation of DPH.
While our search of the available literature revealed no previous reports of DPH-induced PRCA in pregnant women, our search of PubMed revealed 12 cases of DPH-induced PRCA (see Table 2 ) (4-13). The ages of these patients in these cases ranged from 16 to 66 years, and the male-tofemale ratio was 5:7. The duration from the administration of DPH to the onset of PRCA ranged from 30 days to 2.5 years. Among these cases, three individuals exhibited nausea before the manifestation of anemic conditions (7, 6) . In the present study, the serum DPH concentration, which was measured to investigate the cause of the nausea, turned out to be below the effective level. Pritchard et al (7) reported that nausea occurred despite the fact that the serum DPH concentration was below the effective level, as in the present case. Although the association between serum DPH concentration and the onset of PRCA is unknown, caution is required as DPH-induced PRCA can occur even when the serum drug concentration is below the effective level. In eleven of the above cases, the reticulocyte levels at the time of diagnosis were as low as 0‰ to 1‰ (4-11, 13) , as was the case in the present study. In all of the above cases, the treatment involved the discontinuation of DPH administration. Of the 12 cases, seven required a blood transfusion (4, 6, 7, 11, 13) and four required the administration of a steroid (6, 11, 12) . Discontinuation of DPH led to the resolution of anemia in all of the previous cases (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) .
In the present case, erythropoiesis in the bone marrow recovered to a substantial level 3 days after DPH was discontinued. This rapid recovery raised the possibility that the erythropoiesis level might have been improving independent of DPH. On the other hand, there could have been a "maturation arrest" at the level of immature erythroblasts (14) , with DPH discontinuation leading to the rapid recovery. Finally, it took about a month for the hemoglobin level to reach a normal level in the present case, which is within the reported range for DPH-induced PRCA (Table 2) . There have been a few reports suggesting possible mechanisms, including PRCA, of DPH-induced anemia (2, 5). Yunis et al claimed that PRCA is caused by the direct inhibition of DNA replication by DPH (2). Dessypris et al showed, in an in vitro experiment, that DPH can act as a hapten, which can potentially cause the patient's serum IgG to inhibit both erythroid colony-forming unit and erythroid burst-forming unit activities, thereby inducing PRCA (5) . Approximately one month after beginning DPH treatment, the present patient experienced a rapid manifestation of anemia, with Hb levels dropping from around 10 g/dL to 3 g/dL. Considering the lifespan of RBCs, the underlying mechanisms of severe anemia may be related to those of hemolytic anemia, which involves the excessive destruction of RBCs. In fact, the results of the patient's blood test indicated a decreased haptoglobin level and an increased LDH level, indicating the possibility of hemolytic anemia. DPH can induce hemolytic anemia, though such cases are rare (9) . In addition, there have been several reports of PRCA cases suggesting the existence of comorbid hemolytic anemia, as evidenced by increased LDH levels, a positive Coombs' test, or a decreased haptoglobin level (6, 9-11). Although an increased LDH level may also indicate ineffective hematopoiesis, in the present case no findings suggested an ineffective hematopoiesis in the bone marrow. Although the underlying mechanisms of such conditions are unknown, the involvement of an autoimmune process is suspected (9) .
